We are live on ! Find out more
ABCL icon

AbCellera Biologics
ABCL

141 hedge funds and large institutions have $525M invested in AbCellera Biologics in 2025 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 43 increasing their positions, 35 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

84% more call options, than puts

Call options by funds: $9.54M | Put options by funds: $5.18M

59% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 22

42% more capital invested

Capital invested by funds: $371M → $525M (+$154M)

23% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 35

10% more funds holding

Funds holding: 128 → 141 (+13)

1.25% less ownership

Funds ownership: 36.07% → 34.81% (-1.3%)

Holders
141
Holders Change
+13
Holders Change %
+10.16%
% of All Funds
1.85%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
35
Increased
43
Reduced
35
Closed
22
Calls
$9.54M
Puts
$5.18M
Net Calls
+$4.35M
Net Calls Change
+$2.71M

Top Buyers

Rank Fund Capital Flow
1
Bank of America
Bank of America
North Carolina
+$9.67M
2
Morgan Stanley
Morgan Stanley
New York
+$7.91M
3
DCM
Driehaus Capital Management
Illinois
+$5.41M
4
Two Sigma Investments
Two Sigma Investments
New York
+$4.69M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$3.63M

Top Sellers

Rank Fund Capital Flow
1
UBS AM
UBS AM
Illinois
-$29.1M
2
O
OrbiMed
New York
-$11.5M
3
Citadel Advisors
Citadel Advisors
Florida
-$8.29M
4
Millennium Management
Millennium Management
New York
-$4.27M
5
UBS Group
UBS Group
Switzerland
-$4.23M
Name Holding Trade Value Shares
Change 		Change in
Stake
XT
151
XTX Topco
Cayman Islands
– -$228K -66,444 Closed
PCM
152
Prelude Capital Management
New York
– -$222K -64,813 Closed
SG Americas Securities
153
SG Americas Securities
New York
– -$75K -21,979 Closed
GAM
154
GEM Asset Management
Michigan
– -$80.6K -20,000 Closed
MG
155
Marex Group
– -$68.6K -20,000 Closed
SIC
156
Salem Investment Counselors
North Carolina
– -$53.3K -15,550 Closed
Pathstone Holdings
157
Pathstone Holdings
New Jersey
– -$43.9K -12,811 Closed
DC
158
Diametric Capital
Massachusetts
– -$42.2K -12,309 Closed
SA
159
Sanctuary Advisors
Indiana
– -$35.5K -10,359 Closed
CIAM
160
Caitong International Asset Management
Hong Kong
– -$34.7K -10,127 Closed
MYIA
161
Mount Yale Investment Advisors
Colorado
– -$6.53K -1,905 Closed
PFBT
162
Parkside Financial Bank & Trust
Missouri
– -$686 -200 Closed
BIG
163
Brooklyn Investment Group
New York
– -$608 -177 Closed
3 4 5 6
7

ABCL Hedge Fund Activity: Q3 2025 in Review

141 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in AbCellera Biologics (ABCL) for Q3 2025, worth a combined $525M — up 42% from $371M a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new ABCL positions and 22 closed out — a net gain of 13 holders — while 43 added to existing stakes and 35 trimmed.

The largest buyer was Bank of America, adding an estimated $9.67M. The largest seller was UBS AM, exiting entirely with an estimated $29.1M sold.

  • 141 institutional investors held AbCellera Biologics (ABCL) as of Q3 2025, up from 128 in Q2 2025.
  • Funds reported $525M of AbCellera Biologics stock for Q3 2025, up 42% quarter-over-quarter.
  • 35 funds opened new AbCellera Biologics positions in Q3 2025 and 22 closed out, a net change of +13 holders.
  • The largest AbCellera Biologics buyer in Q3 2025 was Bank of America, an estimated $9.67M added.
  • The largest AbCellera Biologics seller in Q3 2025 was UBS AM, an estimated $29.1M sold.

Based on aggregated 13F filings for Q3 2025.